Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PVLA
PALVELLA THERAPEUTICS, INC.
NASDAQ
$157.24
▲ UP 1.14% (1.77)

KEY STATISTICS

Market Cap$2.23 B
52w High$161.38
52w Low$52.36
Dividend Yield—
Frequency—
P/E-32.55
Volume162.22K
Shares Out.14.34M

COMPANY

LEADERSHIP

Wesley H. Kaupinen
CHIEF EXECUTIVE
Wesley H. Kaupinen

COMPENSATION 2026

Salary$575,000
Stock Awards$0
Incentive Plan Pay$359,375
All Other Comp.$643
Total$3,404,904

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 2, 2015
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
29

PRICE TARGET

Target High$270.00
Target Low$207.00
Target Median$226.00
Target Consensus$232.25

UPCOMING EARNINGS

DateNov 10, 2026
DayTuesday
Rev. Est.$16.67K
NOV
10
TUE

SPLIT RECORD

DATETYPERATIO
2024-04-23Reverse1:80

PRICE

$157.24 ▲ UP 1.14% (+$1.77)
OVERLAYS
$154$155$156$1579:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM157.24

About Palvella Therapeutics, Inc.

https://palvellatx.com ↗

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies, including QTORIN rapamycin gel, for rare genetic skin diseases and mTOR-driven skin conditions.

INDUSTRY

Biotechnology

A PRODUCT PALVELLA THERAPEUTICS, INC. IS KNOWN FOR

QTORIN™ 3.9% rapamycin anhydrous gel
QTORIN™ 3.9% rapamycin anhydrous gel

Palvella's lead clinical-stage topical therapy targets rare genetic skin diseases with no FDA-approved treatments, currently in late-stage trials for conditions like microcystic lymphatic and venous malformations.

COMPETITORS

COMPETITOR
BBIO COMPARE
KRYS COMPARE
NVS COMPARE
SLGL COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
103
LISTED HERE
18
RANKED BY POSITION SIZE
XBI
0.58% · 435.9K
VTI
0.00% · 389.7K
IWM
0.05% · 279.0K
SBIO
1.24% · 19.4K
LF
LFSC
2.15% · 17.8K
LABU
0.38% · 14.5K
XRS2.DE
0.05% · 10.0K
FESM
0.02% · 7.1K
GSSC
0.09% · 6.3K
RSSL
0.05% · 5.3K
BBC
0.86% · 2.9K
URTY
0.02% · 430
VETS
0.09% · 223
DFAC
0.00% · 218
TNXT
0.10% · 121
USUE.DE
0.00% · 62
RESM
0.05% · 20
SC0K.DE
0.05% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
64.26%
HOLDERS
238
TOP 12 OF 238 · RANKED BY POSITION SIZE
Bvf Inc/Il
1.2M sh · $72.8M
Suvretta Capital Management, LLC
1.2M sh · $143.78M
First Light Asset Management, LLC
980.8K sh · $122.25M
Jennison Associates LLC
960.6K sh · $146.8M
Blackrock, Inc.
918.4K sh · $140.34M
Frazier Life Sciences Management, L.P.
882.4K sh · $134.85M
State Street Corp
653.2K sh · $99.82M
Price T Rowe Associates Inc /Md/
638.9K sh · $97.63M
Vanguard Group Inc
560.6K sh · $58.68M
Frontier Capital Management Co LLC
478.8K sh · $73.18M
Federated Hermes, Inc.
433.0K sh · $53.98M
Perceptive Advisors LLC
395.1K sh · $24.77M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF OPERATING OFFICER
Goin Kathleen
Sale · 400 shares
2026-08-19
★
OFFICER: CHIEF OPERATING OFFICER
Goin Kathleen
Sale · 2.1K shares
2026-08-19
★
OFFICER: CHIEF OPERATING OFFICER
Goin Kathleen
Purchase · 2.2K shares
2026-08-19
★
OFFICER: CHIEF OPERATING OFFICER
Goin Kathleen
Sale · 2.0K shares
2026-08-19

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 7
OVERWEIGHT 2
OUTPERFORM 1
STRONG BUY 1
11 GRADES IN THE LAST 12 MONTHS
Chardan Capital BUY Stephens & Co. OVERWEIGHT HC Wainwright & Co. BUY BTIG BUY Mizuho OUTPERFORM Truist Securities BUY Canaccord Genuity BUY TD Cowen BUY

SECTORS PEERS

PEERPRICE
NBTX$38.80COMPARE
GHRS$27.81COMPARE
TYRA$28.66COMPARE
KURA$13.22COMPARE
SVRA$5.35COMPARE
ABUS$5.14COMPARE
SPRY$5.63COMPARE
RZLT$4.57COMPARE